Home
overview

As levels of obesity in the developed world continue to rise, more effective treatments for diabetes and cardiovascular disease are in high demand. SMi's conference on Emerging Therapeutic Strategies for Metabolic Disorders will present the pharmaceutical industry with a review of recent developments along with insights into new avenues of research.

This event will approach the subject of metabolic disorders and metabolic syndrome from many different angles. The therapeutic application of metabolic inhibitors, pharmacotherapy for obesity, immune therapy in type I diabetes and receptor agonists are just some of the topics being covered. Speakers will include industry leaders and academic experts from prominent organisations and renowned universities throughout Europe.

 

 View the conference programme   Download the brochure Register for the event
                                                                                                                                                                                                       
     Cardiovascular disease treatments

 

Check out some of the topics being covered at this year's conference:

  • Small molecule therapeutics for lysosomal disorders
  • Novel targets for the treatment of obesity and type II diabetes
  • Treatment of cardiovascular risk in obese and diabetic patients
  • Compounds that alter metabolic activity
  • Inflammatory targets
  • DPP-4 inhibitors and GLP-1 receptor agonists
  • Anti-CD3 monoclonal antibodies
  • New insulin sensitizer drugs
  • The endothelium as a target for pharmacological interventions

 Metabolic dieases drug development strategy

  

  New diabetes treatments

  

Drug Development scientists and product managers in the following areas:

  • Diabetes
  • Obesity
  • Cardiovascular disease
  • Cardiometabolic Diseases
  • Metabolic diseases
  • Metabolic disorders
  • Metabolic syndrome
  • Endocrinology
  • Nutrition
  • Therapeutic antibodies
  • Biotherapeutics
  • Pont of Care

 

Conference programme

8:30 Registration & coffee

9:00 Chairman's opening remarks

Itzik Harosh

Itzik Harosh, Chairman and Chief Scientific Officer, ObeTherapy

9:10 Enteropeptidase: A gene associated with a lean human phenotype as a novel target for the treatment of obesity and type II diabetes

Itzik Harosh

Itzik Harosh, Chairman and Chief Scientific Officer, ObeTherapy

  • How to identify genes associated with a "lean phenotype"
  • Mutated enteropeptidase – A "twiggy gene"
  • Why mutation within enteropeptidase genes are extremely rare
  • Inactivation of enteropeptidase in mice
  • Inhibitors of enteropeptidase
  • 9:50 Quantifying pathophysiological changes in cellular bioenergetics

    Kevin Bittman

    Kevin Bittman, Field Applications Scientist, Seahorse Bioscience

  • Measuring mitochondrial dysfunction in living cells
  • Simultaneous measurement of mitochondrial respiration and glycolysis
  • Screen for compounds that alter metabolic activity
  • In situ analysis of differentiated primary cell cultures
  • 10:30 Morning coffee

    11:10 Novel strategies to treat cardiovascular risk in obese and diabetic patients

    Johannes Zanzinger

    Johannes Zanzinger, Head of Global Licensing, Cardiometabolic Diseases, Boehringer Ingelheim

  • Cardiovascular risk in type II diabetes and obesity – What is special and amenable to drug therapy
  • Treating hyperglycaemia, inflammation, hypertension, and atherosclerosis with single drugs – A realistic goal?
  • Where is the market for novel drugs: Remaining unmet medical need vs. exploding costs of health care
  • 11:50 Inflammatory targets for the treatment of type II diabetes

    Matthew Coghlan

    Matthew Coghlan, Director, Biotherapeutics, AstraZeneca

  • Small molecule advances
  • The potential of monoclonal antibodies
  • Future Challenges
  • 12:30 Networking lunch and afternoon tea

    14:00 Treating dyslipidemia in diabetic patients: small, dense LDL as theurapeutic target for cardiovascular risk reduction

    Manfredi Rizzo

    Manfredi Rizzo, Assistant Professor of Internal Medicine, University Of Palermo

  • Cardiovascular risk in type-2 diabetes: the need of novel theraupetic targets for residual cardiovascular
  • Dyslipidemia in type-2 diabetes
  • Atherogenicity of small, dense LDL
  • The role of small, dense as therapeutic target for cardiovascular risk reduction
  • Current drugs and novel drugs to treat atherogenic small, dense LDL in patients with diabetes
  • 14:40 Microsomal transport protein inhibition in the treatment of hyperlipidaemia

    Anthony Wierzbicki

    Anthony Wierzbicki, Reader in Lipids and Cardiometabolic Prevention, King's College London

  • Overview of the synthesis of beta-lipoproteins describing potential drug targets
  • Microsomal transport protein inhibition - clinical and pharmaceutical approaches
  • Potential for microsomal transport protien inhibition in clinical management of hyperlipidaemia
  • 15:20 Rare metabolic diseases: Money from orphan drugs

    Timothy Cox

    Timothy Cox, Professor of Medicine, University of Cambridge

  • The unusual opportunities of orphan agents for biotechs
  • The application of science and the debt of science to medicine
  • The need to maintain a scientific and marketing initiatives
  • The critical importance of partnerships between academics, industry and patient organizations
  • 16:00 Chairman's closing remarks and close of day one

    8:30 Re-registration & coffee

    9:00 Chairman's opening remarks

    David Leslie

    David Leslie, Professor of Diabetes and Autoimmunity, Barts and The London School of Medicine and Dentistry

    9:10 TM38837 – A second generation peripheral selective CB1 receptor antagonist

    Christian Elling

    Christian Elling, Director, Molecular Pharmacology and Development, 7TM Pharma

  • Preclinical and clinical studies with rimonabant
  • Pharmacological blockage of the cannabinoid 1 (CB1) receptor is efficacious in obesity and type 2 diabetes
  • First generation brain penetrating CB1 antagonists
  • Central side effects excluding them from therapeutic use
  • TM38837 is a novel CB1 receptor antagonist
  • Metabolic efficacy of TM38837 in animals comparable to rimonabant
  • TM38837 as a therapy for obesity, diabetes and related metabolic disorders
  • 9:50 Inhibitors for type 1 11BHSD and their potential clinical impact

    Tony Michael

    Tony Michael , Reader in Reproductive Sciences, Division of Biomedical Sciences, St George's, University of London

  • The pivotal role for 11BHSD isoenzymes in glucocorticoid metabolism
  • 11BHSD1 and diabetes
  • 11BHSD1 and obesity
  • Novel physiological modulators of 11BHSD1
  • 10:30 Morning coffee

    11:00 Fibroblast growth factor-21: A new candidate for glucose homeostasis

    Ebrahim Naderali

    Ebrahim Naderali, Professor of Human Physiology, Liverpool Hope University and Medical Advisor, Endocrinology, Pfizer

  • Discovery of FGF-21
  • Intracellualr signalling associated with FGF-21 action
  • Mode of action of FGF-21
  • Clinical relevance of FGF-21
  • 11:40 Discovery and development of effective DGAT-1 inhibitors

    Andrew Turnbull

    Andrew Turnbull, Associate Director, Cardiovascular and GastroIntestinal Bioscience, AstraZeneca

  • DGAT-1 levels and corresponding resistance to obesity
  • DGAT-1 inhibitors presently undergoing development
  • Potential for treatment of obesity and diabetes
  • 12:20 Networking lunch

    13:50 Why we need new insulin sensitizer drugs

    Michael Cawthorne

    Michael Cawthorne, Director, Clore Laboratory, University of Buckingham

  • Insulin resistance as a core defect in type II diabetes and other metabolic diseases
  • Current insulin sensitizers will shortly be off-patent and have been tainted by claims of side effect issues
  • The glitazones are the only proven therapy to delay islet cell exhaustion
  • New agents are needed with improved efficacy and less side effects
  • 14:30 A perspective on pharmacotherapy for obesity

    Jonathan Arch

    Jonathan Arch, Deputy Director, Metabolic Research, University of Buckingham

  • The problem increases, but options for pharmacotherapy decrease
  • Which general strategies are most likely to succeed?
  • Do drugs in development offer a glimmer of hope?
  • Is the most realistic strategy to target type II diabetes with a drug that causes weight loss?
  • 15:10 Afternoon tea

    15:40 Potential role of zinc-alpha-2-glycoprotein (ZAG) in the treatment of obesity and diabetes

    Michael Tisdale

    Michael Tisdale, Professor of Cancer Biochemistry, Aston University

  • ZAG Increasing lipolysis in white adipose tissue
  • UCP-1 levels in brown adipose tissue
  • Oxidation of glucose and lipids
  • Decreased blood glucose and increased insulin sensitivity
  • 16:20 Antiinflammatory antithromobic strategies to treat atherosclerosis: Novel biotherapeutics

    Fredrik Lönnqvist

    Fredrik Lönnqvist, Managing Director, Translational Medicine Bridges

  • Interlinks between diabetes, obesity, inflammation and cardiovascular disease
  • The endothelium as a key target for pharmacological interventions in oxidative stress and thrombosis
  • Molecular and nano-devices that deliver potent anti-oxidant and anti-thrombotic therapeutic enzymes
  • Promise to provide new intervention opportunities for prevention and treatment of cardiovascular disease
  • 17:00 Chairperson’s closing remarks and close of conference

    +

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.